SI2254870T1 - 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1 - Google Patents

1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1

Info

Publication number
SI2254870T1
SI2254870T1 SI200931404A SI200931404A SI2254870T1 SI 2254870 T1 SI2254870 T1 SI 2254870T1 SI 200931404 A SI200931404 A SI 200931404A SI 200931404 A SI200931404 A SI 200931404A SI 2254870 T1 SI2254870 T1 SI 2254870T1
Authority
SI
Slovenia
Prior art keywords
cx3cr1
mcp
benzyl
expression
treatment
Prior art date
Application number
SI200931404A
Other languages
English (en)
Slovenian (sl)
Inventor
Angelo Guglielmotti
Guido Furlotti
Giorgina Mangano
Nicola Cazzolla
Barbara Garofalo
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Publication of SI2254870T1 publication Critical patent/SI2254870T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
SI200931404A 2008-03-07 2009-03-05 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1 SI2254870T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425139 2008-03-07
EP09718467.5A EP2254870B1 (en) 2008-03-07 2009-03-05 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
PCT/EP2009/052590 WO2009109618A2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40

Publications (1)

Publication Number Publication Date
SI2254870T1 true SI2254870T1 (sl) 2016-05-31

Family

ID=39671487

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200931404A SI2254870T1 (sl) 2008-03-07 2009-03-05 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1
SI200931705T SI2254869T1 (sl) 2008-03-07 2009-03-05 Novi 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji CX3CR1 in p40

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200931705T SI2254869T1 (sl) 2008-03-07 2009-03-05 Novi 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji CX3CR1 in p40

Country Status (25)

Country Link
US (3) US7919518B2 (enExample)
EP (3) EP3181551A1 (enExample)
JP (2) JP5509099B2 (enExample)
KR (2) KR101581828B1 (enExample)
CN (2) CN101945855B (enExample)
AR (2) AR070810A1 (enExample)
AU (2) AU2009221083B2 (enExample)
BR (2) BRPI0907977A2 (enExample)
CA (2) CA2712703C (enExample)
CY (2) CY1117584T1 (enExample)
DK (2) DK2254869T3 (enExample)
EA (2) EA019711B1 (enExample)
ES (2) ES2637009T3 (enExample)
GE (2) GEP20135912B (enExample)
HR (2) HRP20171208T1 (enExample)
HU (1) HUE027098T2 (enExample)
IL (3) IL206893A0 (enExample)
LT (1) LT2254869T (enExample)
MX (2) MX2010009626A (enExample)
PL (2) PL2254869T3 (enExample)
PT (1) PT2254869T (enExample)
SG (1) SG188177A1 (enExample)
SI (2) SI2254870T1 (enExample)
UA (2) UA105170C2 (enExample)
WO (2) WO2009109618A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5509100B2 (ja) * 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用
HRP20160457T1 (hr) 2008-03-07 2016-05-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1 i cx3cr1
BRPI0907977A2 (pt) * 2008-03-07 2015-08-04 Acraf Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
US8350052B2 (en) 2009-08-03 2013-01-08 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required magnesium intermediates
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
AU2013255050B2 (en) * 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2013171316A1 (en) 2012-05-18 2013-11-21 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
HUE032890T2 (hu) * 2012-05-18 2017-11-28 Sanofi Sa Pirazol-származékok és alkalmazásuk LPAR5 antagonsitákként
TW201919579A (zh) 2012-11-09 2019-06-01 霍華德大學 用於牙齒琺瑯質保護之嵌段共聚物
US20170079955A1 (en) * 2014-05-15 2017-03-23 Shelley Romayne Boyd Compositions and methods for treating and diagnosing ocular disorders
WO2016201426A1 (en) 2015-06-12 2016-12-15 Vettore, LLC Mct4 inhibitors for treating disease
EP3310353A4 (en) * 2015-06-16 2019-02-06 Translatum Medicus, Inc. COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES
DK3551625T3 (da) * 2016-12-12 2024-09-02 Vettore Llc Heterocykliske inhibitorer af mct4
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法
WO2024108386A1 (zh) * 2022-11-22 2024-05-30 中国科学院深圳先进技术研究院 抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用
EP4662203A1 (en) * 2023-02-10 2025-12-17 Translatum Medicus Inc. Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US364371A (en) * 1887-06-07 peice
US416359A (en) * 1889-12-03 Sash-fastener
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
WO2000078757A1 (en) 1999-06-17 2000-12-28 Shionogi Bioresearch Corp. Inhibitors of il-12 production
EP1188438A1 (en) 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
ATE417617T1 (de) 2001-03-15 2009-01-15 Seikagaku Kogyo Co Ltd Mittel zur steurung der expression von il-12
JP2005519034A (ja) 2001-11-30 2005-06-30 シンタ ファーマシューティカルズ コーポレーション ピリミジン化合物
US20070142386A1 (en) * 2003-10-07 2007-06-21 Astrazeneca New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
WO2006046739A1 (ja) * 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 炎症性疾患治療剤
EP1819341A4 (en) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
JP2008520712A (ja) 2004-11-19 2008-06-19 シンタ ファーマシューティカルズ コーポレーション ピリミジン化合物及びその使用
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
JP5509100B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用
BRPI0907977A2 (pt) 2008-03-07 2015-08-04 Acraf Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
HRP20160457T1 (hr) 2008-03-07 2016-05-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1 i cx3cr1

Also Published As

Publication number Publication date
IL207131A (en) 2013-02-28
IL215579A0 (en) 2011-11-30
EP2254870B1 (en) 2016-02-24
IL206893A0 (en) 2010-12-30
UA103605C2 (en) 2013-11-11
AU2009221083B2 (en) 2013-11-28
EA019711B1 (ru) 2014-05-30
EA018241B1 (ru) 2013-06-28
CN101945855B (zh) 2014-12-17
US20100311744A1 (en) 2010-12-09
IL207131A0 (en) 2010-12-30
GEP20135912B (en) 2013-08-26
KR101581828B1 (ko) 2015-12-31
MX2010009626A (es) 2010-12-20
CN101945855A (zh) 2011-01-12
CA2712703C (en) 2016-10-11
KR20100133957A (ko) 2010-12-22
HRP20171208T1 (hr) 2017-10-06
CN101952256A (zh) 2011-01-19
DK2254869T3 (en) 2017-09-04
EP2254869B1 (en) 2017-05-31
LT2254869T (lt) 2017-08-10
AR070811A1 (es) 2010-05-05
CN101952256B (zh) 2016-03-16
PL2254869T3 (pl) 2017-10-31
ES2569330T3 (es) 2016-05-10
AU2009221089B2 (en) 2013-12-05
HRP20160462T1 (hr) 2016-06-03
MX2010009623A (es) 2010-09-28
PT2254869T (pt) 2017-07-18
DK2254870T3 (en) 2016-05-17
ES2637009T3 (es) 2017-10-10
US20110003874A1 (en) 2011-01-06
US7919518B2 (en) 2011-04-05
JP5509101B2 (ja) 2014-06-04
KR20100131432A (ko) 2010-12-15
JP5509099B2 (ja) 2014-06-04
EP2254870A2 (en) 2010-12-01
BRPI0907976A2 (pt) 2015-08-04
AU2009221083A1 (en) 2009-09-11
SI2254869T1 (sl) 2017-10-30
SG188177A1 (en) 2013-03-28
CY1119252T1 (el) 2018-02-14
HUE027098T2 (en) 2016-08-29
US8835481B2 (en) 2014-09-16
WO2009109618A3 (en) 2009-12-10
EA201071038A1 (ru) 2011-02-28
JP2011513367A (ja) 2011-04-28
PL2254870T3 (pl) 2016-07-29
IL215579A (en) 2015-06-30
CA2712403A1 (en) 2009-09-11
CY1117584T1 (el) 2017-04-26
KR101599867B1 (ko) 2016-03-04
WO2009109613A3 (en) 2009-12-10
CA2712703A1 (en) 2009-09-11
EA201071040A1 (ru) 2011-02-28
US20110160205A1 (en) 2011-06-30
CA2712403C (en) 2017-06-06
AU2009221089A1 (en) 2009-09-11
WO2009109613A2 (en) 2009-09-11
AR070810A1 (es) 2010-05-05
BRPI0907977A2 (pt) 2015-08-04
WO2009109618A2 (en) 2009-09-11
UA105170C2 (en) 2014-04-25
US8283348B2 (en) 2012-10-09
GEP20135983B (en) 2013-12-10
EP2254869A2 (en) 2010-12-01
EP3181551A1 (en) 2017-06-21
JP2011513365A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
SI2254870T1 (sl) 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1
HRP20191953T8 (hr) DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40
IL207278A0 (en) 1 - benzyl - 3 - hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp - 1, and cx3cr1
ZA201100845B (en) Purine derivatives for use in the treatment of allergic,inflammatory and infectious diseases
IL210803A0 (en) Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
IL217300A0 (en) Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE
HK1145323A (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
TH0901005786A (th) อนุพันธ์พิวรีนเพื่อใช้ในการรักษาโรคภูมิแพ้, อาการอักเสบ และโรคติดเชื้อ